EU OKs first-line use of Roche’s lung cancer drug Alecensa

Roche’s Alecesna has been cleared for use in Europe as a first-line treatment for ALK-positive non-small cell lung cancer (NSCLC), offering a new option for patients newly diagnosed with the disease.

• Source: Pharmatimes
• 483
• December 22, 2017